MA45002A - Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda - Google Patents
Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmdaInfo
- Publication number
- MA45002A MA45002A MA045002A MA45002A MA45002A MA 45002 A MA45002 A MA 45002A MA 045002 A MA045002 A MA 045002A MA 45002 A MA45002 A MA 45002A MA 45002 A MA45002 A MA 45002A
- Authority
- MA
- Morocco
- Prior art keywords
- receptor antagonists
- pure
- nmda
- combination
- acetylcholinesterase inhibitors
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne une combinaison d'un antagoniste pur du récepteur 5-ht6, d'un inhibiteur de l'acétylcholinestérase et d'un antagoniste du récepteur nmda. La présente invention concerne également des antagonistes purs du récepteur 5-ht6 (5-ht6r), ou un ou plusieurs sels pharmaceutiquement acceptables de ceux-ci, en combinaison avec ou comme adjuvant à un inhibiteur de l'acétylcholinestérase et un antagoniste du récepteur de n-méthyl-d-aspartate (nmda), et leur utilisation dans le traitement de troubles cognitifs. La présente invention concerne en outre une composition pharmaceutique contenant ladite combinaison.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| PCT/IB2016/054672 WO2017199070A1 (fr) | 2016-05-18 | 2016-08-03 | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45002A true MA45002A (fr) | 2019-03-27 |
| MA45002B1 MA45002B1 (fr) | 2020-10-28 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45002A MA45002B1 (fr) | 2016-05-18 | 2016-08-03 | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (fr) |
| EP (1) | EP3458039B1 (fr) |
| JP (1) | JP6629464B2 (fr) |
| KR (1) | KR102016120B1 (fr) |
| CN (1) | CN109152751A (fr) |
| AU (1) | AU2016407426B2 (fr) |
| BR (1) | BR112018073410A2 (fr) |
| CA (1) | CA3023836C (fr) |
| CY (1) | CY1123644T1 (fr) |
| DK (1) | DK3458039T3 (fr) |
| EA (1) | EA038087B1 (fr) |
| ES (1) | ES2815555T3 (fr) |
| HK (1) | HK1258022A1 (fr) |
| HR (1) | HRP20201412T1 (fr) |
| HU (1) | HUE052077T2 (fr) |
| IL (1) | IL262920B (fr) |
| LT (1) | LT3458039T (fr) |
| MA (1) | MA45002B1 (fr) |
| MD (1) | MD3458039T2 (fr) |
| MX (1) | MX384146B (fr) |
| NZ (1) | NZ747797A (fr) |
| PL (1) | PL3458039T3 (fr) |
| PT (1) | PT3458039T (fr) |
| RS (1) | RS60849B1 (fr) |
| SG (1) | SG11201809726UA (fr) |
| SI (1) | SI3458039T1 (fr) |
| SM (1) | SMT202000521T1 (fr) |
| WO (1) | WO2017199070A1 (fr) |
| ZA (1) | ZA201807310B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110799189A (zh) * | 2017-07-03 | 2020-02-14 | 苏文生命科学有限公司 | 纯5-ht6受体拮抗剂的新用途 |
| AU2020398082A1 (en) * | 2019-12-02 | 2022-06-16 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
| JP2023510082A (ja) * | 2019-12-02 | 2023-03-13 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者における行動・心理症状を治療するための方法 |
| CN117024326A (zh) * | 2023-07-26 | 2023-11-10 | 平顶山学院 | 5位氨基取代吲哚化合物及其制备方法和在抗乙酰胆碱酯酶药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1509232E (pt) * | 2002-05-31 | 2009-01-07 | Lundbeck & Co As H | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer |
| JP4559230B2 (ja) | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物 |
| JP5628937B2 (ja) * | 2010-01-05 | 2014-11-19 | スベン ライフ サイエンシズ リミティド | ５−ｈｔ６受容体リガンドとしてのスルホン化合物 |
| HUE036008T2 (hu) * | 2013-12-02 | 2018-06-28 | Suven Life Sciences Ltd | Eljárás 1-[(2-brómfenil)szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol-dimezilát-monohidrát nagyüzemi léptékben történõ elõállítására |
| US9840482B2 (en) * | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
-
2016
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2016-08-03 MX MX2018014184A patent/MX384146B/es unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/fr active Active
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 SM SM20200521T patent/SMT202000521T1/it unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/fr not_active Ceased
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/fr active Active
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active Active
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 HK HK19100393.2A patent/HK1258022A1/zh unknown
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2020
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57972B1 (fr) | Inhibiteurs de parp1 | |
| MA48051B1 (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| MA39094A1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA45002A (fr) | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda | |
| MA39984B1 (fr) | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné | |
| GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
| MA34002B1 (fr) | Thérapie antivirale | |
| MA55821B1 (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| RU2009120992A (ru) | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MX2018003930A (es) | Inhibidores de calicreína plasmática humana. | |
| MA45639B1 (fr) | Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase | |
| WO2019032528A8 (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| MA45990A (fr) | Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase | |
| FR3061021B1 (fr) | Antagoniste specifique de tlr4 dans le traitement du myelome multiple | |
| MA45988A (fr) | Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda | |
| MA41311B1 (fr) | Peptides antagonistes du cgrp | |
| EA201892583A1 (ru) | Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора | |
| MA39533A1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| MA46358B1 (fr) | Compositions pharmaceutiques d'antagoniste de 5-ht6 | |
| UA129712C2 (uk) | Композиції для лікування гемангіоми | |
| SE0302331D0 (sv) | New use II | |
| MA57829B1 (fr) | Masupirdine pour le traitement de symptômes comportementaux et psychologiques de démence |